Chronic myelogenous leukemia initiating cells require Polycomb group protein EZH2

Tyrosine kinase inhibitors (TKIs) have revolutionized chronic myelogenous leukemia (CML) management. Disease eradication, however, is hampered by innate resistance of leukemia initiating cells (LICs) to TKI-induced killing, which also provides the basis for subsequent emergence of TKI-resistant muta...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Discov
Main Authors: Xie, Huafeng, Peng, Cong, Huang, Jialiang, Li, Bin E., Kim, Woojin, Smith, Elenoe C., Fujiwara, Yuko, Qi, Jun, Cheloni, Giulia, Das, Partha P., Nguyen, Minh, Li, Shaoguang, Bradner, James E., Orkin, Stuart H.
Formato: Artigo
Idioma:Inglês
Publicado em: 2016
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5096974/
https://ncbi.nlm.nih.gov/pubmed/27630126
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-15-1439
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados